Cargando…
Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients
BACKGROUND AND AIM: Hepatitis C virus (HCV) therapy should be considered without delay in all patients with significant (SIGFIB) or advanced liver fibrosis (ADVFIB). We aimed to investigate the rates of treatment initiation with interferon-free regimens within a screening program for SIGFIB/ADVFIB i...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816107/ https://www.ncbi.nlm.nih.gov/pubmed/28744597 http://dx.doi.org/10.1007/s00508-017-1231-x |
_version_ | 1783300619439702016 |
---|---|
author | Chromy, David Schwabl, Philipp Bucsics, Theresa Scheiner, Bernhard Strassl, Robert Mayer, Florian Aichelburg, Maximilian C. Grabmeier-Pfistershammer, Katharina Trauner, Michael Peck-Radosavljevic, Markus Reiberger, Thomas Mandorfer, Mattias |
author_facet | Chromy, David Schwabl, Philipp Bucsics, Theresa Scheiner, Bernhard Strassl, Robert Mayer, Florian Aichelburg, Maximilian C. Grabmeier-Pfistershammer, Katharina Trauner, Michael Peck-Radosavljevic, Markus Reiberger, Thomas Mandorfer, Mattias |
author_sort | Chromy, David |
collection | PubMed |
description | BACKGROUND AND AIM: Hepatitis C virus (HCV) therapy should be considered without delay in all patients with significant (SIGFIB) or advanced liver fibrosis (ADVFIB). We aimed to investigate the rates of treatment initiation with interferon-free regimens within a screening program for SIGFIB/ADVFIB in human immunodeficiency virus/HCV coinfected patients (HIV/HCV). METHODS: The FIB-4 was calculated in all HIV/HCV from 2014–2016. HIV/HCV were counselled by the HIV clinic and referred to the Division of Gastroenterology and Hepatology for transient elastography (TE) and evaluation for HCV therapy. Patients were stratified by FIB-4 of </≥1.45 (established cut-off for ruling out ADVFIB) and SIGFIB/ADVFIB were defined by liver stiffness >7.1 kPa/>9.5 kPa, respectively. RESULTS: Among 1348 HIV+ patients, 16% (210/1348) had detectable HCV-RNA. One hundred HIV/HCV had a FIB-4 ≥1.45. Among these, 57% (57/100) underwent TE. The majority of these patients had SIGFIB (75%; 43/57) or ADVFIB (37%; 21/57), however, interferon-free treatment was initiated in only 56% (24/43). In addition, fifty-two percent (57/110) of HIV/HCV with FIB-4 <1.45 underwent TE. Interestingly, 40% (23/57) and 18% (10/57) of these patients showed SIGFIB or even ADVFIB, respectively, and 78% (18/23) finally received interferon-free treatment. Overall, only 20% (42/210) of HIV/HCV received interferon-free treatment. CONCLUSION: FIB-4 was not useful for ruling out SIGFIB/ADVFIB in our cohort of HIV/HCV. Treatment was initiated only in a small proportion (20%) of HIV/HCV during the first 2 years of interferon-free treatment availability, although the observed proportion of patients with SIGFIB (assessed by TE) was considerably higher (58%). Thus, it requires the ongoing combined efforts of both HIV and HCV specialists to increase treatment uptake rates in this special population. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi: 10.1007/s00508-017-1231-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5816107 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-58161072018-02-27 Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients Chromy, David Schwabl, Philipp Bucsics, Theresa Scheiner, Bernhard Strassl, Robert Mayer, Florian Aichelburg, Maximilian C. Grabmeier-Pfistershammer, Katharina Trauner, Michael Peck-Radosavljevic, Markus Reiberger, Thomas Mandorfer, Mattias Wien Klin Wochenschr Original Article BACKGROUND AND AIM: Hepatitis C virus (HCV) therapy should be considered without delay in all patients with significant (SIGFIB) or advanced liver fibrosis (ADVFIB). We aimed to investigate the rates of treatment initiation with interferon-free regimens within a screening program for SIGFIB/ADVFIB in human immunodeficiency virus/HCV coinfected patients (HIV/HCV). METHODS: The FIB-4 was calculated in all HIV/HCV from 2014–2016. HIV/HCV were counselled by the HIV clinic and referred to the Division of Gastroenterology and Hepatology for transient elastography (TE) and evaluation for HCV therapy. Patients were stratified by FIB-4 of </≥1.45 (established cut-off for ruling out ADVFIB) and SIGFIB/ADVFIB were defined by liver stiffness >7.1 kPa/>9.5 kPa, respectively. RESULTS: Among 1348 HIV+ patients, 16% (210/1348) had detectable HCV-RNA. One hundred HIV/HCV had a FIB-4 ≥1.45. Among these, 57% (57/100) underwent TE. The majority of these patients had SIGFIB (75%; 43/57) or ADVFIB (37%; 21/57), however, interferon-free treatment was initiated in only 56% (24/43). In addition, fifty-two percent (57/110) of HIV/HCV with FIB-4 <1.45 underwent TE. Interestingly, 40% (23/57) and 18% (10/57) of these patients showed SIGFIB or even ADVFIB, respectively, and 78% (18/23) finally received interferon-free treatment. Overall, only 20% (42/210) of HIV/HCV received interferon-free treatment. CONCLUSION: FIB-4 was not useful for ruling out SIGFIB/ADVFIB in our cohort of HIV/HCV. Treatment was initiated only in a small proportion (20%) of HIV/HCV during the first 2 years of interferon-free treatment availability, although the observed proportion of patients with SIGFIB (assessed by TE) was considerably higher (58%). Thus, it requires the ongoing combined efforts of both HIV and HCV specialists to increase treatment uptake rates in this special population. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi: 10.1007/s00508-017-1231-x) contains supplementary material, which is available to authorized users. Springer Vienna 2017-07-25 2018 /pmc/articles/PMC5816107/ /pubmed/28744597 http://dx.doi.org/10.1007/s00508-017-1231-x Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Chromy, David Schwabl, Philipp Bucsics, Theresa Scheiner, Bernhard Strassl, Robert Mayer, Florian Aichelburg, Maximilian C. Grabmeier-Pfistershammer, Katharina Trauner, Michael Peck-Radosavljevic, Markus Reiberger, Thomas Mandorfer, Mattias Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients |
title | Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients |
title_full | Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients |
title_fullStr | Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients |
title_full_unstemmed | Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients |
title_short | Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients |
title_sort | non-invasive liver fibrosis assessment and hcv treatment initiation within a systematic screening program in hiv/hcv coinfected patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816107/ https://www.ncbi.nlm.nih.gov/pubmed/28744597 http://dx.doi.org/10.1007/s00508-017-1231-x |
work_keys_str_mv | AT chromydavid noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients AT schwablphilipp noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients AT bucsicstheresa noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients AT scheinerbernhard noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients AT strasslrobert noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients AT mayerflorian noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients AT aichelburgmaximilianc noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients AT grabmeierpfistershammerkatharina noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients AT traunermichael noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients AT peckradosavljevicmarkus noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients AT reibergerthomas noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients AT mandorfermattias noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients |